Cancer Immunotherapy by Targeting Unique Cancer Mutations

Immunology Interest Group Dr. Steve Rosenberg received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg has pioneered the development of effective immunotherapies and gene therapies for patients with advanced cancers. His studies of the adoptive transfer of genetically modified lymphocytes have resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas. His current research is aimed at defining the host immune response of patients to their cancers. These studies emphasize the ability of human lymphocytes to recognize unique cancer antigens and the identification of anti-tumor T cell receptors that can be exploited to develop new cell transfer immunotherapies for the treatment of cancer patients. Dr. Rosenberg also oversees the Surgery Branch’s clinical program aimed at translating scientific advances into effective immunotherapies for patients with cancer. For more information go to http://sigs.nih.gov/immunology/Pages/default.aspxAir date: 4/29/2015 4:15:00 PM
Source: Videocast - All Events - Category: Journals (General) Tags: Upcoming Events Source Type: video